Atorvastatin reduced major cardiovascular events by about 30% among apparently healthy adults aged 70 and older in the landmark STAREE trial, delivering some of the strongest randomized evidence yet that statin therapy can provide meaningful primary cardiovascular prevention well into older age. The Australian study enrolled 9,971 community-dwelling participants without known cardiovascular disease, diabetes or dementia and compared atorvastatin 40 mg once daily with placebo over roughly six years.
The result addresses a clinical uncertainty that has persisted despite decades of statin use. Evidence that lowering low-density lipoprotein cholesterol prevents heart attacks and strokes is extensive among middle-aged adults and people who already have cardiovascular disease, but patients older than 70 or 75 have historically been underrepresented in major primary-prevention trials. STAREE was designed specifically to answer whether starting a statin in relatively healthy older people meaningfully improves outcomes rather than simply lowering a laboratory value.
How much did atorvastatin reduce cardiovascular events in the STAREE trial?
Participants receiving atorvastatin experienced substantially fewer first major cardiovascular events than those receiving placebo. Reported event rates were approximately 6.0% with atorvastatin and 8.3% with placebo, corresponding to a hazard ratio of about 0.70 and a relative risk reduction of roughly 30%. The cardiovascular endpoint included serious outcomes such as cardiovascular death, myocardial infarction and stroke, while the trial followed participants for a median approaching six years.
The size of the trial strengthens the finding. STAREE enrolled 9,971 people with an average age of approximately 75 years, including more than 4,000 participants aged 75 or older. About 52% were women, and participants were recruited through primary-care practices across Australia rather than from a narrowly selected specialist population.
That community-based design increases the practical relevance of the findings because the people physicians see when discussing primary cardiovascular prevention in their seventies often resemble the STAREE population more closely than participants in earlier cholesterol trials.
Did statins also help older people remain independent for longer?
This is where the findings become more nuanced.
STAREE had another major objective beyond preventing cardiovascular events: determining whether atorvastatin could extend disability-free survival, defined around remaining alive without dementia or persistent physical disability. The trial did not demonstrate a statistically significant improvement on that broader outcome, with the disability-free survival result remaining similar between atorvastatin and placebo.
That means the study should not be interpreted as showing that statins delay ageing generally or guarantee longer independent living. Their clearest demonstrated benefit was cardiovascular.
This distinction could actually make clinical conversations easier. Physicians do not need to present atorvastatin as a longevity medicine. STAREE instead provides stronger evidence that an older person who has not yet suffered a heart attack or stroke can still reduce the probability of experiencing a first major cardiovascular event.
Why has prescribing statins after age 70 been controversial?
The problem has never been that cholesterol suddenly stops mattering at a certain birthday. The difficulty has been balancing increasing cardiovascular risk against changing competing risks, medication burden and limited randomized evidence.
A person in their seventies may already take medicines for blood pressure, arthritis, gastrointestinal conditions, sleep or other chronic problems. Adding another preventive drug makes sense only when the expected benefit remains meaningful during that individual’s likely lifetime.
Older adults may also be more vulnerable to drug interactions and side effects, while physicians need to consider frailty, kidney or liver disease and overall treatment burden.
Previous guidelines therefore had substantially stronger evidence supporting statin initiation at younger ages than in healthy people beyond 75. STAREE fills an important part of that evidence gap rather than simply extrapolating results from 55-year-olds to 80-year-olds.
Does STAREE mean everyone over 70 should start atorvastatin?
No. The study supports a stronger evidence base for discussing statins, not an automatic prescription based on age alone.
STAREE enrolled comparatively healthy older adults. People with established cardiovascular disease already have separate indications for cholesterol-lowering therapy, while patients with significant frailty, severe illness, medication intolerance or limited life expectancy can have a very different risk-benefit balance.
Individual decisions still depend on cholesterol levels, blood pressure, smoking, kidney function, family history, medications and patient preference.
The findings are therefore likely to influence guidelines by making age alone a weaker reason to avoid starting therapy. Monash University researchers said they expect the evidence to inform future recommendations for cardiovascular prevention in older people.
What about muscle problems, memory loss and other statin fears?
Concerns about statins frequently include muscle symptoms, diabetes risk and possible cognitive effects, and these worries can discourage otherwise eligible patients from taking the drugs.
STAREE is especially useful because participants were followed for years and because disability and dementia were incorporated into the study rather than ignored. The trial did not show an improvement in disability-free survival, but importantly it also did not produce evidence that atorvastatin caused the feared large deterioration in healthy ageing that might negate its cardiovascular benefit.
That does not mean individual patients cannot experience adverse effects. Muscle symptoms and liver-enzyme abnormalities can occur, and treatment still requires clinical judgment.
The broader evidence increasingly supports a more individualized conversation rather than a simplistic choice between “statins are harmless” and “statins are dangerous.”
Why could this become one of the most important statin studies in years?
Statins are inexpensive, widely available and already familiar to primary-care physicians. That makes STAREE different from a breakthrough trial involving a medicine costing tens of thousands of dollars.
Even a modest change in prescribing behavior could affect millions of older adults because cardiovascular risk rises sharply with age.
Monash University noted that almost 10,000 participants were followed in a study involving thousands of general practitioners, making STAREE one of the largest cardiovascular-prevention trials conducted specifically in older people.
The public-health impact could consequently be much larger than the novelty of the medicine suggests. Atorvastatin itself is old. The important development is discovering more precisely who still benefits from it.
What should patients over 70 do with the STAREE results?
The study should provide a reason for discussion rather than self-medication.
An older adult without cardiovascular disease who previously assumed that starting a statin was pointless because of age may now have stronger evidence to discuss with a physician. Conversely, patients already taking statins should not change treatment solely because of headlines about the trial.
The central finding is straightforward but important: cardiovascular prevention does not stop being biologically useful when a patient reaches 70.
STAREE suggests that among appropriately selected older adults, a medicine that has existed for decades can still prevent a meaningful proportion of first cardiovascular events. The next major step will be whether national and international guidelines translate that 30% reduction into broader statin recommendations for healthy older populations.
